NASDAQ:VCELVericel Stock Price, Forecast & News

Vericel's stock was trading at $12.08 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VCEL stock has increased by 27.0% and is now trading at $15.34.
View which stocks have been most impacted by COVID-19.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vericel.

Vericel is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Vericel.

Vericel Corp (NASDAQ:VCEL) issued its earnings results on Wednesday, August, 5th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.21) by $0.03. The biotechnology company earned $20 million during the quarter, compared to analyst estimates of $19.31 million. The business's quarterly revenue was down 23.7% on a year-over-year basis. During the same period last year, the firm earned ($0.05) EPS.
View Vericel's earnings history.

Vericel updated its second quarter 2020 Pre-Market earnings guidance on Thursday, July, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $20-20 million, compared to the consensus revenue estimate of $15.79 million.

5 Wall Street analysts have issued twelve-month price objectives for Vericel's shares. Their forecasts range from $21.00 to $32.00. On average, they expect Vericel's stock price to reach $24.25 in the next twelve months. This suggests a possible upside of 58.1% from the stock's current price.
View analysts' price targets for Vericel.

Headlines about VCEL stock have trended somewhat negative this week, InfoTrie reports. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Vericel earned a news sentiment score of -1.8 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Vericel.

Some companies that are related to Vericel include Twist Bioscience (TWST), Immunovant (IMVT), Legend Biotech (PCVX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Mesoblast (MESO), Sangamo Therapeutics (SGMO), BAVARIAN NORDIC/S (BVNRY), Revolution Medicines (RVMD), Coherus Biosciences (CHRS), Forma Therapeutics (FMTX), NanoString Technologies (NSTG), Cortexyme (CRTX), Regenxbio (RGNX) and Beam Therapeutics (BEAM).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Momo (MOMO), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), Dynavax Technologies (DVAX), Amarin (AMRN), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX) and Verastem (VSTM).

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Vericel's stock is owned by many different institutional and retail investors. Top institutional investors include RTW Investments LP (8.51%), Vanguard Group Inc. (5.26%), Fort Washington Investment Advisors Inc. OH (1.55%), GW&K Investment Management LLC (1.47%), New York State Common Retirement Fund (1.30%) and Summit Creek Advisors LLC (1.05%). Company insiders that own Vericel stock include Dominick Colangelo, Gerard J Michel, Michael Halpin, Paul K Wotton and Steven C Gilman.
View institutional ownership trends for Vericel.

VCEL stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, RTW Investments LP, Emerald Advisers LLC, Marshall Wace LLP, Silvercrest Asset Management Group LLC, Vanguard Group Inc., GW&K Investment Management LLC, and Falcon Point Capital LLC. Company insiders that have sold Vericel company stock in the last year include Dominick Colangelo, Gerard J Michel, and Michael Halpin.
View insider buying and selling activity for Vericel.

VCEL stock was acquired by a variety of institutional investors in the last quarter, including New York State Common Retirement Fund, Summit Creek Advisors LLC, Prosight Management LP, Cadence Capital Management LLC, Goldman Sachs Group Inc., WINTON GROUP Ltd, Conestoga Capital Advisors LLC, and Rafferty Asset Management LLC.
View insider buying and selling activity for Vericel.

Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCEL stock can currently be purchased for approximately $15.34.

Vericel has a market capitalization of $694.14 million and generates $117.85 million in revenue each year. The biotechnology company earns $-9,660,000.00 in net income (profit) each year or $0.18 on an earnings per share basis. Vericel employs 216 workers across the globe.

The official website for Vericel is www.vcel.com.

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-588-5555 or via email at [email protected]